07:55 AM EDT, 07/11/2024 (MT Newswires) -- Satellos Bioscience ( MSCLF ) filed a clinical research proposal to Australia's health regulator for permission to conduct a first-in-human Phase 1 clinical trial of SAT-3247, a proprietary, oral small molecule drug being being developed to regenerate skeletal muscle lost in Duchenne muscular dystrophy (DMD) and other degenerative diseases or injuries.

The Phase 1 trial will enroll healthy volunteers to assess the safety and pharmacokinetic properties of SAT-3247. Depending on the results of that study, Satellos will advance SAT-3247 into clinical trials with DMD patients early next year.

"Prior to submitting our regulatory documentation, we conducted our preclinical and toxicology studies to the standards of relevant global regulatory bodies," said Phil Lambert, Chief Scientific Officer of Satellos. "Thus, we expect to be able to leverage these results for additional Phase 1 and subsequent clinical trials in Australia and further jurisdictions including the United States and Canada, where we plan to advance into trials with DMD patients."